| Revenue growth | 30% Y-o-Y for Q4FY26; 11% Y-o-Y for full year FY26. |
|---|---|
| Margins | EBITDA margin at 2.28%, impacted by low-margin initial API sales. |
| Demand visibility | Stability expected in capsule business; API volumes to grow gradually. |
| Management confidence | High; confident in restoring growth and profitability in FY27. |
Growth
Revenue grew 30% Y-o-Y to ₹58.45 Cr; FY26 revenue reached ₹187.20 Cr, up 11% Y-o-Y. Standalone capsule sales boosted by ₹6 Cr deferred revenue.
Outlook
Commissioned new HPMC line for US markets; API commercial production started March 2026. Expects ₹67 Cr PLI incentive over 6 years.
Risks
Y-o-Y EBITDA dropped 70%; PAT and EPS saw significant losses due to operational stabilization costs and API segment ramp-up.
Earnings Call filed with BSE, NSE: NATCAPSUQ. Summary written with AI assistance from the document.
Natural Capsules Ltd: key numbers
- Share price
- ₹161.01
- Market cap
- ₹167.6 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -7.8×Sector 47.4×
- Promoter holding
- 50.92%-0.12% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Annual General Meeting
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Fund Raise of ₹10.01 Cr
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
- Value
- ₹10.01 Cr
Natural Capsules Board Meeting Date
Natural Capsules Limited is holding a board meeting at shorter notice on September 02, 2026, to revise the issue price and quantity for its proposed preferential issue.
Natural Capsules Annual General Meeting
Natural Capsules Limited has issued a notice for an EGM to approve a Rs. 10.00 Crore preferential allotment of equity shares and warrants to a promoter.
- Value
- ₹10.00 Cr
Natural Capsules Investor Presentation: Key Takeaways
NCL reported Q1FY27 revenue of ₹48.71 Cr (+8% Y-o-Y) with EBITDA at ₹1.12 Cr. Strategy focuses on scaling steroidal API volumes and HPMC line conversions to optimize capacity.
Natural Capsules Results Update
Natural Capsules Limited announced its Q1FY27 financial results. The company highlighted operational performance, market demand, and new contract manufacturing agreements for its business segments.